SCHEMBL18952969

SCHEMBL18952969

O=C=NCCN1C(=O)C=CC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 10/20 0.50
FAAH O00519 5/20 0.50
ALDH1A1 P00352 2/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
HSP90AA1 P07900 1/20 0.48
TLR9 Q9NR96 1/20 0.48
TP53 P04637 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
XBP1 P17861 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
RECQL P46063 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GPR35 Q9HC97 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
PTGS1 P23219 7/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4589431 0.88 MGLL (0.58) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL473707 0.84 MGLL (0.63) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL4589798 0.84 MGLL (0.63) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL19252437 0.81 MGLL (0.48) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL18952994 0.74 CHRM2 (0.34) MGLLFAAH
SCHEMBL145737 0.72 MGLL (0.77) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14678413 0.72 MGLL (0.77) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL22268167 0.70
SCHEMBL1502692 0.70 NPSR1 (0.31) NPSR1
SCHEMBL34594 0.70 MGLL (0.56) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2023-02-07 US disclosed
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2023-02-07 US disclosed
CN-108368143-B Monomaleimide functionalized platinum compounds for cancer therapy 维也纳医科大学 2022-02-01 CN disclosed
EP-3386997-B1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY UNIV WIEN MED (AT) 2021-06-30 EP disclosed
EP-3386997-B1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY UNIV WIEN MED (AT) 2021-06-30 EP disclosed
US-20210002313-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2021-01-07 US disclosed
US-20210002313-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2021-01-07 US disclosed
US-10723748-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2020-07-28 US disclosed
US-10723748-B2 Monomaleimide-functionalized platinum compounds for cancer therapy MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2020-07-28 US disclosed
US-20180354979-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY Universität Wien (AT) 2018-12-13 US disclosed
EP-3386997-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY Medizinische Universität Wien (AT) 2018-10-17 EP disclosed
CN-108368143-A Monomaleimide functionalized platinum compounds for cancer therapy 维也纳医科大学 2018-08-03 CN disclosed
WO-2017097986-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2017-06-15 WO disclosed
WO-2017097986-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2017-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002313-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY FOLR2, FOLR1, SLC19A1 MGLL 3581/4885FAAH 3461/4885ALDH1A1 982/4885
US-10723748-B2 Monomaleimide-functionalized platinum compounds for cancer therapy FOLR2, FOLR1, SLC19A1 MGLL 3581/4885FAAH 3461/4885ALDH1A1 982/4885
US-11572379-B2 Monomaleimide-functionalized platinum compounds for cancer therapy FOLR2, FOLR1, SLC19A1 MGLL 3581/4885FAAH 3461/4885ALDH1A1 982/4885
US-20180354979-A1 MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY FOLR2, FOLR1, SLC19A1 MGLL 3581/4885FAAH 3461/4885ALDH1A1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.